Stocks Health care MENS
NASDAQ · Health careJyong Biotech Ltd. (MENS)
It posted a net loss of $4.7M. At December 31, 2025 it held $1.2M in cash against $2.1M of debt. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on May 15, 2026.
What Jyong Biotech Ltd. does
Jyong Biotech Ltd. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker MENS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$4.7M | -$0.06 | n/a |
| 2025 | n/a | -$3M | -$0.04 | n/a |
| 2023 | n/a | -$4.4M | -$0.06 | n/a |
Latest SEC filings
What Jyong Biotech Ltd. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- May 15, 2026Annual report (foreign issuer) 20-F · period to December 31, 2025
- April 29, 2026Form NT 20-F filing NT 20-F
- April 24, 2026Activist stake (5% or more) SCHEDULE 13D
- February 6, 2026
- January 9, 2026
- June 30, 2025Form SP 15D2 filing SP 15D2
- June 20, 2025
- June 18, 2025
- June 6, 2025Form POS AM filing POS AM
- April 23, 2025Form POS AM filing POS AM
Questions about MENS
What does Jyong Biotech Ltd. do?
Jyong Biotech Ltd. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker MENS.
Is Jyong Biotech Ltd. profitable?
No. In fiscal 2025 it reported a net loss of $4.7M.
When did Jyong Biotech Ltd. last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on May 15, 2026. It covers the period to December 31, 2025.
Similar companies
Follow MENS
Get an email when Jyong Biotech Ltd. files with the SEC: results, executive changes, material agreements and annual reports.
Follow MENS: get an email when it filesWhere the numbers come from
Financial figures are the values Jyong Biotech Ltd. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.